Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 4,699 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Control Condition Clear all
Not listed Phase 2 Interventional Accepts healthy volunteers

A Scalable Weight Control Intervention for Adolescents

NCT02426346
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Behavioral weight control, Group-based physical activity, Group-based incentives, Parent-based incentives
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
13 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 18, 2026, 1:32 AM EDT
Completed Phase 1 Interventional

Hyperbaric Oxygen Treatment (HBOT) During Methadone Tapering

NCT05924022
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Hyperbaric Oxygen Treatment Full, Hyperbaric Oxygen Treatment Sham, Hyperbaric Oxygen Treatment Partial Pressure
Combination Product
Lead sponsor
Washington State University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 18, 2026, 1:32 AM EDT
Completed Not applicable Interventional

Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders

NCT04221269
View directory record Official record
Conditions
Schizophrenia, Suicide
Interventions
Enhanced Treatment as Usual, Coping Long-term with Active Suicide Program for Schizophrenia
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 18, 2026, 1:32 AM EDT
Completed Phase 2 Interventional Results available

Study of Vitamin D and Effect on Heart Disease and Insulin Resistance

NCT01093417
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Vitamin D Deficiency, HIV Infections
Interventions
Vitamin D, Placebo
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 18, 2026, 1:32 AM EDT
Completed Phase 2 Interventional

A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

NCT05265325
View directory record Official record
Conditions
Renal Anemia
Interventions
AND017 capsules TIW, AND017 capsules QW, epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars
Drug
Lead sponsor
Kind Pharmaceuticals LLC
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Pine Bluff, Arkansas • Riverside, California • Lone Tree, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 18, 2026, 1:32 AM EDT
Recruiting Not applicable Interventional

Pilot Trial of Spiritual Care Interventions for Patients With Cancer

NCT06811376
View directory record Official record
Conditions
Advanced Cancer
Interventions
Spiritual Care Intervention #1, Spiritual Care Intervention #2
Behavioral · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Brooklyn, New York • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 18, 2026, 1:32 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC

NCT05291689
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Colitis, Ulcerative
Interventions
MORF-057
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Tampa, Florida • Lafayette, Louisiana • Freehold, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 18, 2026, 1:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Decision Support to Improve System Naloxone Co-prescribing

NCT06271668
View directory record Official record
Conditions
Medication Abuse, Harm Reduction, Opioid Overdose, Opioid Prescribing
Interventions
Naloxone Co-prescribing Clinical Decision Support (CDS)
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 89 Years
Enrollment
114,272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 1:32 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Biomarker Cost-Benefit Analysis of EFNEP

NCT05558085
View directory record Official record
Conditions
Chronic Disease
Interventions
Expanded Food and Nutrition Education Program (EFNEP)
Behavioral
Lead sponsor
South Dakota State University
Other
Eligibility
18 Years to 50 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Fort Collins, Colorado • Gainesville, Florida • College Park, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 18, 2026, 1:32 AM EDT
Completed No phase listed Observational

Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)

NCT04320485
View directory record Official record
Conditions
Anthrax
Interventions
Active Anthrax Detect™ Plus (AAD Plus)
Diagnostic Test
Lead sponsor
InBios International, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Tempe, Arizona • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 18, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

NCT00891735
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
99
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 18, 2026, 1:32 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

NCT03675308
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Placebo, Risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
59
States / cities
Anniston, Alabama • Peoria, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 18, 2026, 1:32 AM EDT
Completed Phase 1 Interventional

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs

NCT04286789
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Low dose ORTD-1, Low dose vehicle control, High dose ORTD-1, High dose vehicle control
Drug
Lead sponsor
Oryn Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Los Angeles, California • Tustin, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 18, 2026, 1:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Writing Wrongs: Expressive Writing for Microaggressions

NCT06276725
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Discriminatory Stress, Microaggression
Interventions
Writing Wrongs
Behavioral
Lead sponsor
Auburn University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 18, 2026, 1:32 AM EDT
Recruiting Not applicable Interventional

Remote Cardiac Rehab for Adolescents With Congenital Heart Disease

NCT06015191
View directory record Official record
Conditions
Congenital Heart Disease in Children
Interventions
Remote Cardiac Rehabilitation, Active Control
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 19 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 18, 2026, 1:32 AM EDT
Completed Not applicable Interventional

The Use of Libre to Improve Metabolic Control and Reduce Reliance on Medication

NCT04632849
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GEM + CGM
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
35 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 18, 2026, 1:32 AM EDT
Recruiting Phase 2 Interventional

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

NCT07840326
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS), Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive MS, Non-Active SPMS, Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Interventions
SUN-627, Placebo
Drug · Other
Lead sponsor
Sundance Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Raleigh, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 18, 2026, 1:32 AM EDT
Recruiting Phase 2 Interventional

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

NCT07142291
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg)
Drug
Lead sponsor
PhenoNet, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 18, 2026, 1:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Efficacy of Cranial Electrotherapy Stimulation (CES) for the Treatment of Major Depressive Disorder

NCT03222752
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cranial Electrotherapy Stimulation, Sham Cranial Electrotherapy Stimulation
Device
Lead sponsor
Electromedical Products International, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Forest, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 18, 2026, 1:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurophysiologic Correlates of Hypersomnia

NCT01719315
View directory record Official record
Conditions
Major Depressive Disorder, Primary Hypersomnia, Bipolar Disorder, Narcolepsy, Primary Insomnia
Interventions
Acoustical slow wave induction
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 18, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

NCT00917384
View directory record Official record
Conditions
Gastric Cancer, Adenocarcinoma
Interventions
ramucirumab, Placebo, Best Supportive Care (BSC)
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • La Jolla, California • Redlands, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 18, 2026, 1:32 AM EDT
Recruiting Not applicable Interventional

Optimizing Gait Rehabilitation for Veterans With Non-traumatic Lower Limb Amputation

NCT03995238
View directory record Official record
Conditions
Transtibial Amputation, Peripheral Artery Disease, Diabetes Mellitus
Interventions
Error-augmentation gait training, Error-correction gait training, Supervised walking
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 89 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 18, 2026, 1:32 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008

NCT00308438
View directory record Official record
Conditions
Crohn's Disease
Interventions
Teduglutide (ALX-0600)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
20
States / cities
Tucson, Arizona • Lakewood, Colorado • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 18, 2026, 1:32 AM EDT
Not yet recruiting Not applicable Interventional

DecNef for Auditory Verbal Hallucinations (AVH) in Schizophrenia

NCT07779226
View directory record Official record
Conditions
Schizophrenia Disorder, Schizoaffecitve Disorder
Interventions
Decoded Neurofeedback
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 18, 2026, 1:32 AM EDT